LLL12 

LLL12 is a small molecule inhibitor of STAT3 that inhibits STAT3 phosphorylation. LLL12 enhanced the inhibitory effect of Cisplatin (HY-17394) and Paclitaxel (HY-B0015) on ovarian cancer cell formation, migration, and growth^[1].

LLL12 (0.01-1 μM; 72 h) inhibits cell viability of ovarian cancer cell lines with or without Cisplatin (0.5 μM, 2.5 μM) and Paclitaxel (0.25 μM, 0.5 μM).^[1].
LLL12 (0.25-1.0 μM; 72 h) inhibit STAT3 phosphorylation (Tyr705) in ovarian cancer cell lines^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

LLL12 (5 mg/kg; i.p.; once daily for 13 d) shows strong growth inhibition activity in mouse osteosarcoma cells and tumor growth^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

303.29

C₁₄H₉NO₅S

1260247-42-4

O=S(C(C=CC=C1C(C2=C3C=CC=C2O)=O)=C1C3=O)(N)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zhang R, et al. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells. Oncol Rep. 2020 Sep;44(3):1224-1232.  [Content Brief]

  [2]. Onimoe GI, et al. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs. 2012 Jun;30(3):916-26.  [Content Brief]